Reuther Tobias, Kettmann Corinna, Scheer Martin, Kochel Michael, Iida Seiji, Kubler Alexander C
Department of Craniomaxillofacial and Plastic Surgery, University of Cologne, Cologne, Germany.
Cells Tissues Organs. 2006;183(1):32-40. doi: 10.1159/000094904.
In reconstructive medicine, the clinical use of cryopreservation techniques depends on the absence of infectious agents such as prions. Therefore, we investigated the viability and differentiation of human osteoblast-like cells during replacement of fetal bovine serum in vitro. The aim of the present study is to replace the potentially infectious supplement fetal bovine serum during the cryopreservation procedure in order to perform future clinical trials. We used a cryopreservation technique with Me(2)SO for human osteoblast-like cells of iliac cancellous bone. In the cell culture of cryopreserved and fresh osteoblast-like cells, we substituted Dulbecco's modification of Eagle's medium (DMEM)/Ham's F12 plus 1% penicillin/streptomycin with autologous serum, human serum albumin and Biseko for fetal bovine serum. For the fourth treatment group, we removed fetal bovine serum without replacing it. DMEM/Ham's F12 plus 1% penicillin/streptomycin with fetal bovine serum served as the control group. After 4, 7, 14 and 21 days of culture for the cryopreserved and noncryopreserved cells, we performed cell counting, a WST-1 test, ELISA for collagen type I, and osteocalcin. The activity of alkaline phosphatase was also measured. The best results were obtained for the group with autologous serum as a supplement after thawing, exceeding the other groups with regard to proliferation rate. Most viable cells were observed with no replacement before freezing and after thawing of the cells. With regard to differentiation, the cultures with autologous serum after thawing of the cells showed little concentration of the differentiation markers, probably due to early contact inhibition of the cells in vitro. With regard to effort and outcome, the most promising group for cryopreservation was the one with DMEM/Ham's F12 plus 1% penicillin/streptomycin alone before freezing, especially when osteoblast-like cells were cultured in medium with autologous serum after thawing. This is important, as this in vitro setting resembles the in vivo situation when cryopreserved bone is transplanted. These findings indicate that, for clinical purposes, fetal bovine serum can be removed for cryopreservation of iliac cancellous bone with minor loss of viability.
在重建医学中,冷冻保存技术的临床应用取决于是否不存在诸如朊病毒等感染因子。因此,我们研究了体外更换胎牛血清期间人成骨样细胞的活力和分化情况。本研究的目的是在冷冻保存过程中替代具有潜在传染性的补充物胎牛血清,以便开展未来的临床试验。我们对来自髂骨松质骨的人成骨样细胞采用含二甲基亚砜(Me(2)SO)的冷冻保存技术。在冷冻保存的和成骨样细胞的新鲜细胞培养中,我们用自体血清、人血清白蛋白和Biseko替代了含有1%青霉素/链霉素的杜氏改良伊格尔培养基(DMEM)/哈姆氏F12中的胎牛血清。对于第四治疗组,我们去除了胎牛血清但未进行替代。含有胎牛血清的DMEM/哈姆氏F12加1%青霉素/链霉素作为对照组。在对冷冻保存的和未冷冻保存的细胞进行4、7、14和21天的培养后,我们进行了细胞计数、WST - 1检测、I型胶原蛋白酶联免疫吸附测定(ELISA)和骨钙素检测。还测量了碱性磷酸酶的活性。解冻后以自体血清作为补充物的组获得了最佳结果,在增殖率方面超过了其他组。在细胞冷冻前和解冻后不进行替代的情况下观察到的活细胞最多。关于分化,细胞解冻后含自体血清的培养物中分化标志物的浓度较低,这可能是由于细胞在体外早期接触抑制所致。就努力程度和结果而言,冷冻保存最有前景的组是冷冻前仅使用含1%青霉素/链霉素的DMEM/哈姆氏F12的组,尤其是当解冻后的成骨样细胞在含自体血清的培养基中培养时。这很重要,因为这种体外环境类似于冷冻保存的骨移植时的体内情况。这些发现表明,出于临床目的,在冷冻保存髂骨松质骨时可以去除胎牛血清,而活力损失较小。